Checkpoint inhibitor therapy targeting PD-1/PDL-1 restore immune system function and represents the current standard of care for patients with metastatic MSI-H/MMRd CRC (André et al. 2020) and represent a therapy option for metastatic MMRd GC (Mishima et al. 2019; Marabelle et al. 2020; Kubota et al. 2020). Here, CD274 is linked to colorectal carcinoma.